News releases from Allergan plc
Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline
September 14, 2018
- Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline -
Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments
September 12, 2018
Allergan to Host Medical Aesthetics Day Event on September 14, 2018
September 10, 2018
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September 14, 2018. The investor event will...
The Most Exciting Advance in Skincare is Here: Introducing the SkinMedica® LUMIVIVE™ System
September 06, 2018
NOVEL, DUAL-ACTING PRODUCT REVITALIZES AND PROTECTS SKIN AGAINST BLUE LIGHT AND ENVIRONMENTAL AGRESSORS AROUND THE CLOCK
Allergan to Present at the 2018 Morgan Stanley Global Healthcare Conference
September 04, 2018
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Morgan Stanley Global...
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Wells Fargo Healthcare...
Allergan Continues Board Refreshment Process
August 29, 2018
Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application
August 21, 2018
Allergan plc (NYSE: AGN) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for ulipristal...
Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process
August 08, 2018
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
August 06, 2018
Reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care
Allergan Reports Strong Second Quarter 2018 Results Including GAAP Net Revenues of $4.1 Billion
July 25, 2018
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
July 23, 2018
- New Molecule Recognized as a Potentially Innovative Treatment for MDD, a Serious Condition with Persistent Unmet Need -
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
July 19, 2018
Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12-week regimen, achieved the primary endpoint of non-inferiority to monthly...
- New Artificial Tear Improves Clarity of Vision, Protects The Eye's Surface And Treats The Signs And Symptoms Of Dry Eye -
Allergan's Study in Chronic Migraine Receives Migraine Research Award at the American Headache Society's 60th Annual Scientific Meeting
June 28, 2018
- Award-winning Chronic Migraine epidemiology study (CaMEO) and 17 additional presentations showcase Allergan innovation and leadership in research for migraine treatment and prevention -
Allergan plc (NYSE: AGN) today announced that it intends to release second quarter 2018 financial results on Thursday, July 26, 2018, prior to the open of U.S. financial markets.
Allergan Continues Active Board Refreshment Process
June 14, 2018
Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension
June 13, 2018
-An investigational implant being developed as the first sustained-release drop-free treatment option for patients-
Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
June 11, 2018
Allergan and Actress Shay Mitchell Join Forces to Inspire Women to Know Their Birth Control
June 07, 2018
Know Your Birth Control® Launches New 'BC Trivia' Quiz to Encourage Informed Conversations Around Contraception
Allergan Responds to Public Shareholder Letter
June 05, 2018
Allergan plc (NYSE: AGN) today issued the following statement in response to a public shareholder letter:
Allergan Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients and their Caregivers to Hold on to Hope
June 05, 2018
The 'Hold on to Hope' movement takes to social media in recognition of Alzheimer's & Brain Awareness during the month of June
Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules
May 29, 2018
Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous...
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the Bernstein 34th Annual Strategic Decisions Conference in...
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Bank of America Merrill Lynch Healthcare Conference...
John Davidson Elected to Allergan Board of Directors
May 03, 2018
Allergan plc (NYSE: AGN) today announced that John Davidson has been elected to its Board of Directors. Mr. Davidson and the other directors standing for re-election to Allergan's Board were elected at...
Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA) 2018 Annual Meeting
May 02, 2018
Eight accepted abstracts will showcase new data across schizophrenia, bipolar I disorder and major depressive disorder (MDD)
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will present at the Deutsche Bank 43rd Annual Health Care Conference in...